Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma

Chinese Medical Journal

Volumn 127, Issue 7, 2014, Pages 1328-1333

  Wen, Ming ^a,b   Xu, Wei Li ^a   Ren, Li Li ^b   Gao, Fei ^a,c   Cui, Nai Peng ^b   Wen, Jun Ye ^a   Li, Xin Jiang ^a   Lin, Lin ^a   Ma, Zhen Feng ^b   Chen, Bao Ping ^b   Cai, Jian Hui ^a,c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

^c HEBEI GENERAL HOSPITAL   (China)

Author keywords

Adoptive transfer; Cytotoxic T lymphocyte; Immunotherapy; Melanoma; Naive T cell; Pooled T cells

Indexed keywords

CANCER GROWTH FACTOR; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; MELANOMA B16; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL CULTURE; MELANOMA, EXPERIMENTAL; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL;

EID: 84897939435     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123364     Document Type: Article

References (24)

1. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GMCSF for colorectal cancer. Mol Ther 2008; 16: 782-790.
2. Grégoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 2003; 21: 791-794.
3. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
4. Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, Yoshimoto T. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol 2005; 175: 1686-1693.
5. Helmich BK, Dutton RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 2001; 166: 6500-6508.
6. Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, et al. Tumor-specifc CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002; 168: 3484-3492.
7. Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, et al. Antigen presented by tumors in vivo determines the nature of CD8+T-cell cytotoxicity. Cancer Res 2009; 69: 6615-6623.
8. Riquelme E, Carreño LJ, González PA, Kalergis AM. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. Eur J Immunol 2009; 39: 2259-2269.
9. Dudley ME, Wundfrlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor anti-gen-specific T-lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25: 243-251.
10. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U SA 2009; 106: 17469-17474.
11. Brown DM. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol 2010; 262: 89-95.
12. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, et al. CD4 cells can be more effcient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-5354.
13. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005; 54: 587-598.
14. Lin CT, Chang TC, Shaw SW, Cheng PJ, Huang CT, Chao A, et al. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity. Vaccine 2006; 24: 6199-6207.
15. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003; 9: 540-547.
16. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U SA 2004; 101: 14639-14645.
17. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005; 434: 88-93.
18. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specifc CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207: 651-667.
19. Lord EM, Penney DP, Sutherland RM, Cooper RA Jr. Morphological and functional characteristics of cells infltrating and destroying tumor multicellular spheroids in vivo. Virchows Archiv 1979; 31: 103-116.
20. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
21. Burocchi A, Pittoni P, Gorzanelli A, Colombo MP, Piconese S. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur J Immunol 2011; 41: 3615-3626.
22. D'Alise AM, Ergun A, Hill JA, Mathis D, Benoist C. A cluster of coregulated genes determines TGF-beta-induced regulatory T-cell (Treg) dysfunction in NOD mice. Proc Natl Acad Sci U S A 2011; 108: 8737-8742.
23. Cui NP, Xie SJ, Han JS, Ma ZF, Chen BP, Cai JH. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice. Chin Med J 2012; 125: 794-800.
24. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333: 167-179.